Home/Recce Pharmaceuticals/John Prendergast

JP

John Prendergast

Executive Chairman

Recce Pharmaceuticals

Therapeutic Areas

Antibacterial Antiviral Infectious Diseases

Recce Pharmaceuticals Pipeline

Drug	Indication	Phase
RECCE® 327	Broad‑spectrum bacterial infections (including ABSSSI, diabetic foot, burn wounds, HAP/VAP)	Phase 3
RECCE® 435	Oral broad‑spectrum antibacterial	Preclinical
RECCE® 529	Viral infections	Preclinical

Leadership Team at Recce Pharmaceuticals

Managing Director & CEO

Michele Dilizia

Executive Director & Chief Scientific Officer

Executive Director & Principal Quality Chemist

Chief Medical Advisor & Non‑Executive Director

View full Recce Pharmaceuticals profile